Skip to main content

Gilead: Hep C Prescriptions Hold at 94% Among New Patients

Citigroup’s Robyn Karnauskas and Mohit Bansal have the latest IMS prescription data for Gilead Sciences’ (GILD) hepatitis C treatments, with new starts falling slightly week over week but holding a 94% share among the new patients. We are in week #4 of new competition launch. However, new pt. starts are tracking 3% below last Q […]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.